Abstract
The striatum receives dense dopaminergic projections making it a key region of the dopaminergic system. Its dysfunction has been implicated in various conditions including Parkinson’s disease and substance use disorder. However, the investigation of dopamine-specific functioning in humans is problematic as the striatum is highly interconnected and current MRI approaches are unable to differentiate between dopaminergic and other projections. Here, we demonstrate that “connectopic mapping” –a novel approach for characterizing fine-grained and overlapping modes of functional connectivity– can be used to map dopaminergic projections and as such, enables the investigation of dopamine-related functioning both in health and disease.
We applied connectopic mapping to resting-state functional MRI data of the Human Connectome Project (population cohort; N=839) and selected the second-order striatal connectivity mode for further analyses. We first validated its specificity to dopaminergic projections by demonstrating a very high spatial correlation (r=0.884) with dopamine transporter availability –a marker of dopaminergic projections– derived from DaT-SPECT scans of 209 healthy control subjects of the Parkinson’s Progression Markers Initiative. Next, we obtained the subject-specific second-order modes from 20 controls, and 39 Parkinson’s disease patients scanned under placebo and under dopamine replacement therapy (L-DOPA), and show that our proposed marker of dopamine function indeed tracks Parkinson’s disease diagnosis, symptom severity and sensitivity to L-DOPA. Finally, across 30 daily alcohol users and 38 daily smokers of the Human Connectome Project, we establish strong associations between the second-order striatal connectivity mode and self-reported weekly use of alcohol and nicotine.
Our findings provide compelling evidence that the second-order mode of functional connectivity in striatum maps onto dopaminergic projections, tracks inter-individual differences in symptom severity and L-DOPA sensitivity in Parkinson’s disease patients, and exhibits strong associations with levels of nicotine and alcohol use in a population-based cohort. We hereby provide a new biomarker for dopamine-related dysfunction in the human brain with potential clinical utility that could foster insights into the neurobiological underpinnings of various dopamine-associated conditions.
Competing Interest Statement
CFB is director and shareholder in SBGneuro Ltd. All other authors report no competing interests.
Funding Statement
This work was supported by the Netherlands Organization for Scientific Research Vidi Grant No. 864-12-004 (to CFB), Vici Grant No. 17854 (to CFB), Vidi Grant No. 016.156.415 (to AM), Veni Grant No. 016.171.068 (to KVH), Veni Grant No. 91617077 (to RH) and NWO-CAS Grant No. 012-200-013 (to CFB, providing funds to MF). MO was supported by ZonMW Rubicon Grant No. 452172019. RH was also funded by a grant of the Dutch Brain Foundation grant F2013(10-15). The Centre of Expertise for Parkinson & Movement Disorders of the Radboud University Medical Centre was supported by a centre of excellence grant of the Parkinsons Foundation. We further made use of HCP data that were provided by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centres that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Centre for Systems Neuroscience at Washington University. We also used data from the Parkinsons Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinsons Research funding partners Abbvie, Avid Radiopharmaceuticals, Biogen Idec, BioLegend, Bristol- Myers Squibb, Eli Lilly & Co., F. Hoffman-La Roche, Ltd., GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale Discovery, Piramal, Pfizer, Sanofi Genzyme, Servier, Takeda, Teva, and UCB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical-ethical committee at the Radboud University Medical Center and local ethical committees from centers involved in the collection of the publicly available data from the Human Connectome Project (HCP) and Parkinson's Progression Markers Initiative (PPMI)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We made use of publicly available data from the HCP dataset (S1200 release) and from the PPMI dataset (see https://www.humanconnectome.org/study/hcp-young-adult/document/1200-subjects-data-release and https://www.ppmi-info.org/access-data-specimens/download-data). The subject identifiers from the HCP and PPMI datasets used in our analyses can be found in Supplementary Tables S5-S7. Please note that the subject identifiers from the subset of HCP subjects included in the nicotine-use and alcohol-use analyses cannot be provided, since these are based on the HCP restricted data. The code used for the connectopic mapping procedure is available at the following Github repository: https://github.com/koenhaak/congrads. The remaining data and analysis code are available from the corresponding author upon reasonable request.
